Method for preparing a concentrate of polyvalent immunoglobulin

Patent metadata

Field	Value
Publication number	US-9718856-B2
Application number	US-201214131944-A
Country	US
Kind code	B2
Filing date	Jul 11, 2012
Priority date	Jul 11, 2011
Publication date	Aug 1, 2017
Grant date	Aug 1, 2017

Abstract

The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.

First claim

The invention claimed is:

1. A method for preparing a concentrate of human polyvalent immunoglobulins from an initial solution of blood plasma or a fraction of plasma enriched with immunoglobulins, comprising:
(a) removing protein contaminants by contacting the initial solution of blood plasma or a fraction of plasma enriched with immunoglobulins with caprylic acid in order to obtain a solution free of proteases, wherein the concentration of caprylic acid ranges from 0.5 to 1.5% by volume of caprylic acid per volume of initial solution of blood plasma or a fraction of plasma enriched with immunoglobulins to be treated, and
(b) fluidized bed chromatography of the mixed-mode type of the solution free of proteases, to obtain a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma.

2. The method according to claim 1 , wherein the step for removing protein contaminants with caprylic acid (a) is carried out at a pH between 4.3 and 4.9.

3. The method according to claim 2 , wherein the step for removing protein contaminants with caprylic acid (a) is carried out at a pH between 4.6 and 4.8.

4. The method according to claim 1 , further comprising between the step for removing protein contaminants with caprylic acid (a) and the fluidized bed chromatography step (b), a clarification step at an acid pH.

5. The method according to claim 4 , wherein the clarification step is by depth filtration.

6. The method according to claim 1 , wherein the fluidized bed chromatography step of the mixed-mode type comprises:
loading on a chromatography column equilibrated beforehand with a buffer at a pH between 4.5 and 8, the solution having undergone the clarification step by depth filtration, adjusted beforehand to the same pH,
washing the loaded column with a buffer solution until all non-adsorbed proteins on the column are removed,
eluting polyvalent immunoglobulins adsorbed on the column with an elution buffer adjusted to a pH between 8 and 10, and
recovering the solution enriched with human polyvalent immunoglobulins.

7. The method according to claim 1 further comprising, after step (b), one or more of the following steps:
(i) a viral inactivation step,
(ii) a step for anion exchange chromatography of the solution obtained at the end of step (i),
(iii) a step for removing anti-A and anti-B antibodies from the solution obtained at the end of step (ii),
(iv) a filtration step through nanometric filters with decreasing porosity from 100 to 15 nm,
(v) a concentration step by ultrafiltration of the solution from step (iv) associated with a formulation step,
(vi) and then a conventional sterilizing filtration step.

8. The method according to claim 1 , wherein the initial solution is a plasma fraction enriched with immunoglobulins by fractionation with ethanol or by separation with chromatography.

9. The method according to claim 8 , wherein the initial solution is a I+II+III precipitate or a II+III precipitate obtained from blood plasma fractionated with ethanol, and put back into solution.

10. The method according to claim 9 , wherein the I+II+III precipitate or the II+III precipitate is put back into solution in purified water for injection or in a solution containing ions.

11. The method according to claim 10 , wherein the solution containing ions is a solution comprising NaCl at a concentration of less than or equal to 20 mM.

12. The method according to claim 11 , wherein the solution containing ions is a solution comprising NaCl at a concentration between 5 and 15 mM.

13. The method according to claim 12 , wherein the solution containing ions is a solution comprising NaCl at a concentration equal to 10 mM.

14. The method according to claim 9 , wherein the I+II+III precipitate or the II+III precipitate is treated with CaCl 2 solution, the concentration of which is less than or equal to 20 mM.

15. The method according to claim 14 , wherein the I+II+III precipitate or the II+III precipitate is treated with CaCl 2 solution, the concentration of which is between 5 and 15 mM.

16. The method according to claim 15 , wherein the I+II+III precipitate or the II+III precipitate is treated with a 10 mM CaCl 2 solution.

17. The method according to claim 1 , comprising:
(i) a step for removing protein contaminants with caprylic acid,
(ii) a clarification step by depth filtration,
(iii) a fluidized bed chromatography step of the “mixed-mode” type,
(iv) a viral inactivation step with solvent/detergent treatment,
(v) an anion exchange chromatography step,
(vi) a step for removing anti-A and anti-B antibodies,
(vii) filtration through nanometric filters with decreasing porosity from 100 to 15 nm,
(viii) a step for concentrating by ultrafiltration the solution from the preceding step associated with a formulation step, and then a conventional sterilizing filtration step.

18. The method according to claim 1 , further comprising the following steps:
(a) adding to the concentrate of human polyvalent immunoglobulins obtained according to claim 1 , one or several pharmaceutically acceptable stabilizers, and
(b) optionally, freezing or freeze-drying the pharmaceutical preparation obtained in the preceding step;
so that the pharmaceutical preparation is in a liquid, frozen or freeze-dried form.

19. The method according to claim 1 , wherein the concentration of caprylic acid ranges from 0.8 to 1.2%.

20. The method according to claim 19 , wherein the concentration of caprylic acid ranges from 0.9 to 1.1%.

21. A method for preparing a concentrate of human polyvalent immunoglobulins from an initial solution of blood plasma or a fraction of plasma enriched with immunoglobulins, comprising:
(a) removing protein contaminants by contacting the initial solution of blood plasma or the fraction of plasma enriched with immunoglobulins with caprylic acid in order to obtain a solution free of proteases, wherein the concentration of caprylic acid ranges from 0.9 to 1.1% by volume of caprylic acid per volume of initial solution of blood plasma or the fraction of plasma enriched with immunoglobulins to be treated, and
(b) fluidized bed chromatography of the mixed-mode type of the solution free of proteases, to obtain a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma.

Assignees

• Chtourou Abdessatar
• Bataille Damien
• Michaux Georges
• Lab Francais Du Fractionnement

Inventors

• Chtourou Abdessatar
• Bataille Damien
• Michaux Georges

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title